Arete Wealth Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Arete Wealth Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,531	Closed	-$15K	–	724
2024 Q4	$15K	Hold	2,531	–	–	﹤0.01%	742
2024 Q3	$25K	Sell	2,531 -188	-7%	-$2.53K	﹤0.01%	694
2024 Q2	$56K	Buy	+2,719	New	+$91K	﹤0.01%	704
2024 Q1	–	Sell	-6,825	Closed	-$322K	–	426
2023 Q4	$322K	Buy	+6,825	New	+$379K	0.02%	537

Other funds holding BTAI

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Arete Wealth Advisors's BTAI Position: Q1 2025 in Review

Arete Wealth Advisors sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 2,531 shares — an estimated $15K sold.

Arete Wealth Advisors first reported a position in BTAI in Q4 2023 and held it in 4 quarters. The position peaked at $322K in Q4 2023. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

Arete Wealth Advisors reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
Arete Wealth Advisors sold 2,531 BioXcel Therapeutics shares in Q1 2025, an estimated $15K.
Arete Wealth Advisors first reported a position in BioXcel Therapeutics in Q4 2023 and held it in 4 quarters.
Arete Wealth Advisors's BioXcel Therapeutics position peaked at $322K in Q4 2023.
31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on Arete Wealth Advisors's 13F filing for Q1 2025, filed 16 May 2025.